Bandiera, C.; Locatelli, I.; Courlet, P.; Cardoso, E.; Zaman, K.; Stravodimou, A.; Dolcan, A.; Sarivalasis, A.; Zurcher, J.-P.; Aedo-Lopez, V.;
et al. Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study. Cancers 2023, 15, 316.
https://doi.org/10.3390/cancers15010316
AMA Style
Bandiera C, Locatelli I, Courlet P, Cardoso E, Zaman K, Stravodimou A, Dolcan A, Sarivalasis A, Zurcher J-P, Aedo-Lopez V,
et al. Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study. Cancers. 2023; 15(1):316.
https://doi.org/10.3390/cancers15010316
Chicago/Turabian Style
Bandiera, Carole, Isabella Locatelli, Perrine Courlet, Evelina Cardoso, Khalil Zaman, Athina Stravodimou, Ana Dolcan, Apostolos Sarivalasis, Jean-Philippe Zurcher, Veronica Aedo-Lopez,
and et al. 2023. "Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study" Cancers 15, no. 1: 316.
https://doi.org/10.3390/cancers15010316
APA Style
Bandiera, C., Locatelli, I., Courlet, P., Cardoso, E., Zaman, K., Stravodimou, A., Dolcan, A., Sarivalasis, A., Zurcher, J.-P., Aedo-Lopez, V., Dotta-Celio, J., Peters, S., Guidi, M., Wagner, A. D., Csajka, C., & Schneider, M. P.
(2023). Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study. Cancers, 15(1), 316.
https://doi.org/10.3390/cancers15010316
